UQ Prof Udantha Abeyratne and University team in major breakthrough Source : Dæhæna – Monthly e-Newsletter November 2022 – Queensland Sri Lankans Pfizer has acquired University of Queensland (UQ) startup ResApp Health Limited. ResApp, an ASXlisted company, has developed simple and inexpensive smartphone technology to accurately identify respiratory diseases based on cough analysis. Put it simply, it can diagnose COVID-19 and other respiratory illnesses by listening to someone cough. The technology records a patient’s cough on a smartphone and analyses sounds and simple symptoms, such as a runny nose, to diagnose and measure the severity of a range of chronic and acute diseases, including asthma, pneumonia, bronchiolitis, croup and chronic obstructive pulmonary disease. The UQ technology was developed by (Sri Lankan) Associate Professor Udantha Abeyratne and his UQ team. Dr Abeyratne said that they worked closely with paediatricians and respiratory physicians to develop the diagnostic technology. “When I open up my ...

Read More →

Queensland based Sri Lankan professor receives $179 million on his innovations Source:Island A Brisbane-based company that invented a smartphone app it says can diagnose COVID-19 and other respiratory illnesses by listening to someone cough has been purchased by Pfizer for nearly $180 million.ResApp Health Limited uses diagnostic technology developed by Associate Professor Udantha Abeyratne and his research team at the University of Queensland (UQ) to record and analyse a patient’s coughs on a smartphone. The app also considers the self-reporting of simple symptoms like a runny nose or fever to diagnose and measure the severity of a range of pulmonary diseases, including asthma and pneumonia.Pfizer, which is one of the world’s largest bio-pharmaceutical companies, offered to buy ResApp earlier this year when the company announced positive results for its COVID-19 screening test. ...

Read More →

The Hon. Greg Hunt MP Minister for Health MEDIA RELEASE  Image Source:the Island Online 11 December 2020 Australia secures 20 million extra Astra Zeneca vaccines for onshore manufacturing to cover entire population and a further 11 million Novavax Update on University of Queensland On the basis of scientific advice, the Australian Government has secured an additional 20 million doses of the promising AstraZeneca COVID-19 vaccine, strengthening Australia’s position for whole-of-population vaccination. This will mean a total delivery of 53.8 million Astra Zeneca vaccine doses in 2021, covering the whole of population requirements. The extra 20 million doses of the Astra Zeneca vaccine will be produced within Australia by CSL. Our advice remains that Australia remains on track for first vaccinations in March, and completion of whole of population in 2021. In addition, a further 11 million doses of the Novavax vaccine will be purchased, bringing the total for this vaccine ...

Read More →